News Beijing Konruns Pharmaceutical Co.,Ltd.

Equities

603590

CNE1000036K3

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 30/04/2024 am IST			5-day change	1st Jan Change
29.58 ^CNY	-0.87%		+0.34%	-22.32%

25/04	Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
08/04	Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	08/04	CI
Konruns Pharma Enrolls First Subject in Phase 3 Study of Cancer Drug	06/02	MT
Beijing Konruns Pharmaceutical Gets Nod to Test KC1036 Tablets as Esophagus Cancer Treatment	27/12	MT
Konruns Pharmaceutical Gets Clearance for Clinical Trial of Sarcoma Treatment	20/12	MT
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	27/23/27	CI
Certain A Shares of Beijing Konruns Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 27-AUG-2023.	27/23/27	CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	31/23/31	CI
Chengdu WestGene Biomedical Technology Co., Ltd. announced that it has received $63.25 million in funding from Qingdao Honline Huaxin Asset Management Co., Ltd., Beijing Konruns Pharmaceutical Co.,Ltd., Hangzhou Tigermed Consulting Co., Ltd, Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd., Yingke Innovation Asset Management Co., Ltd.	20/23/20	CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	25/23/25	CI
Chengdu WestGene Biomedical Technology Co., Ltd. announced that it has received $21.45 million in funding from Qingdao Honline Huaxin Asset Management Co., Ltd.,Yingke Innovation Asset Management Co., Ltd.,Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd. and Hangzhou Tigermed Consulting Co., Ltd.	06/22/06	CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	25/22/25	CI
Certain A Shares of Beijing Konruns Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 27-AUG-2022.	27/22/27	CI
Beijing Konruns Pharmaceutical Co.,Ltd. cancelled the transaction announced on March 1, 2021	15/22/15	CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22/22/22	CI
Tranche Update on Beijing Konruns Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on January 21, 2021.	20/22/20	CI
Beijing Konruns Pharmaceutical Co.,Ltd.'s Equity Buyback announced on January 21, 2021, has expired with 2,273,523 shares, representing 1.44% for CNY 79.31 million.	19/22/19	CI
Tranche Update on Beijing Konruns Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on January 21, 2021.	05/22/05	CI
Beijing Konruns Pharmaceutical Co.,Ltd. completed the acquisition of 13.70% stake in Beijing Konruns Biotechnology Co., Ltd. from NT Pharma Pacific Company Limited.	04/21/04	CI
Beijing Konruns Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	25/21/25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Beijing Konruns Pharmaceutical Co.,Ltd.

Equities

603590

CNE1000036K3

Summary

Filters